Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Biotie to present at The Rodman & Renshaw 10th Annual Healthcare Conference, in New York, NY.
Live webcast will be available at www.biotie.com
Biotie Therapies Corp. (NASDAQ OMX: BTH1V) announced today that Dr. Timo Veromaa, President and Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Global Healthcare Conference in New York on Wednesday November 12, 2008 at 11:10 a.m. local time (6:10 p.m. Finnish time).
The audio and slide presentation will be webcast live and will be available for 90 days at www.biotie.com. For more information on the conference: http://www.rodm.com/conferences?id=19
Dr. Timo Veromaa will also present at Sijoitus-Invest 2008 Conference in Helsinki, Finland on Thursday, November 13 at 02:00 p.m. local time.
For further information:
Biotie Therapies Corp. Timo Veromaa, President and CEO Tel: +358 2 274 8900 timo.veromaa@biotie.com www.biotie.com
Biotie Therapies Corp.
Biotie is a drug development company focusing on dependence disorders, inflammatory diseases and thrombosis. The most advanced programs are nalmefene for dependence disorders (phase III in alcoholism) and VAP-1 fully human monoclonal antibody for the treatment of inflammatory diseases (phase I). The nalmefene program is partnered worldwide, with Lundbeck as a key partner (license agreement with EUR 82 million milestone package plus royalties). Roche is a key partner in the inflammation programs with an option for the VAP-1 antibody program for a EUR 5 million option fee.
Biotie announced on October 24, 2008 its intention to acquire elbion GmbH, a German pharmaceutical company. The combination of the two businesses will take place by a share exchange and is to create a leading European company in the field of discovery and development of therapeutics for central nervous system (addiction, psychotic disorders) and inflammatory diseases (rheumatoid arthritis, psoriasis and inflammatory diseases of the respiratory system). The transaction is expected to close November 14, 2008.
Biotie's shares are quoted on the NASDAQ OMX Helsinki Ltd (Small cap, Healthcare).
For more information, please refer to www.biotie.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
